Aurora Cannabis Inc (TSE:ACB) Senior Officer Allan John Cleiren sold 33,000 shares of the firm’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of C$12.12, for a total value of C$399,960.00. Following the completion of the sale, the insider now directly owns 51,120 shares of the company’s stock, valued at C$619,574.40.
Shares of TSE ACB opened at C$12.32 on Tuesday. The firm has a market capitalization of $12.17 billion and a PE ratio of -124.44. Aurora Cannabis Inc has a fifty-two week low of C$5.29 and a fifty-two week high of C$16.24. The company has a debt-to-equity ratio of 8.08, a current ratio of 3.31 and a quick ratio of 1.89.
Aurora Cannabis (TSE:ACB) last announced its quarterly earnings results on Monday, February 11th. The company reported C($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of C($0.06) by C$0.01. The company had revenue of C$54.18 million during the quarter, compared to analysts’ expectations of C$52.13 million. As a group, equities research analysts predict that Aurora Cannabis Inc will post 0.0299747682090031 earnings per share for the current year.
A number of analysts have issued reports on the company. Bank of America reissued a “buy” rating and issued a C$15.00 target price on shares of Aurora Cannabis in a research report on Wednesday, April 17th. Cowen reissued an “outperform” rating and issued a C$14.00 target price on shares of Aurora Cannabis in a research report on Tuesday, March 5th. Jefferies Financial Group reissued a “buy” rating and issued a C$12.00 target price on shares of Aurora Cannabis in a research report on Monday, February 25th. Seaport Global Securities reissued a “neutral” rating on shares of Aurora Cannabis in a research report on Thursday, February 21st. Finally, Eight Capital decreased their target price on Aurora Cannabis from C$17.00 to C$15.00 in a research report on Wednesday, January 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aurora Cannabis presently has an average rating of “Buy” and an average target price of C$13.80.
About Aurora Cannabis
Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution.
See Also: Diversification For Individual Investors
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.